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Open access undera b s t r a c t
Ethnopharmacological relevance: Tabebuia avellanedae Lorentz ex Griseb is a plant employed in tropical
America folk medicine for the treatment of several diseases, including depressive disorders.
Aim of the study: To investigate the ability of Tabebuia avellanedae ethanolic extract (EET) administered
chronically to cause an antidepressant-like effect in the tail suspension test (TST), a predictive test of
antidepressant activity, and to reverse behavioral (hyperactivity, anhedonic-like behavior and
increased immobility time in the TST) and biochemical changes induced by olfactory bulbectomy
(OB), a model of depression, in mice.
Materials and methods: Mice were submitted to OB to induce depressive-related behaviors, which were
evaluated in the open-ﬁeld test (hyperactivity), splash test (loss of motivational and self-care behavior
indicative of an anhedonic-like behavior) and TST (increased immobility time). Phosphorylation levels
of Akt, GSK-3b, ERK1/2 and CREB, as well as BDNF immunocontent, were evaluated in the hippocampus
of bulbectomized mice or sham-operated mice treated for 14 days by p.o. route with EET or vehicle.
Results: EET (10 and 30 mg/kg) given 14 days by p.o route to mice reduced the immobility time in the
TST without altering locomotor activity, an indicative of an antidepressant-like effect. EET per se
increased both CREB (Ser133) and GSK-3b (Ser9) phosphorylation (at doses of 10–30 and 30 mg/kg,
respectively) in sham-operated mice. OB caused hyperactivity, loss of motivational and self-care
behavior, increased immobility time in the TST and an increase in CREB and ERK1 phosphorylation, as
well as BDNF immunocontent. EET abolished all these OB-induced alterations except the increment of
CREB phosphorylation. Akt (Ser473) and ERK2 phosphorylation levels were not altered in any group.
Conclusions: EET ability to abolish the behavioral changes induced by OB was accompanied by
modulation of ERK1 and BDNF signaling pathways, being a promising target of EET. Results indicate
that this plant could constitute an attractive strategy for the management of depressive disorders, once
more validating the traditional use of this plant.
& 2012 Elsevier Ireland Ltd. Open access under the Elsevier OA license. 1. Introduction
Depression is a chronic, recurring and potentially life-threatening
illness that affects up to 17% of the population across the globe, Brain-derived-neurotrophic
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x: þ55 48 3721 9672.
 the Elsevier OA license. (Kessler et al., 2005). It is projected from the World Health
Organization to be the second cause of morbidity and mortality
worldwide by 2020 (Murray and Lopez, 1997). Depressive symp-
toms include somatic and cognitive alterations such as: depressed
mood, anhedonia (loss of interest or pleasure in almost all
activities), irritability, feelings of hopelessness, worthlessness or
guilt, decreased ability to concentrate and think, decreased or
increased appetite, weight loss or weight gain, insomnia or
hypersomnia, psychomotor retardation or agitation, fatigue, low
energy and recurrent thoughts of death and suicide. Although the
current pharmacotherapy of depression includes a battery of
drugs, many are inconsistently effective and exert undesirable
side effects (Morilak and Frazer, 2007). Therefore, considerable
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approaches for the management of depressive disorders.
Tabebuia avellanedae Lorentz ex Griseb (Bignoniaceae) is a tree
native to tropical rain forests in the northeast of Brazil commonly
known as ‘‘pau d’arco’’ or ‘‘ipeˆ-roxo’’. There are several ethno-
pharmacological uses for the barks of this plant. It is called
‘‘divine tree’’ by indigenous peoples of South America, because
according to them, it is one of the most effective, economical and
versatile remedies against a multitude of acute and chronic
diseases (Lu¨ebeck, 1999). Colombians use the bark infusion as
stimulant of central nervous system (Jones, 1995); Bahamians
commonly use the bark decoction to prepare an energizing tonic
for strength (Jones, 1995), and Brazilians use this plant to treat
malaria, cancer, fever, stomach disorders, bacterial and fungal
infections and to relief of a variety of mental and emotional states
such as anxiety, poor memory, irritability and depression
(Lu¨ebeck, 1999; Go´mez Castellanos et al., 2009). Indeed, it was
demonstrated that Tabebuia avellanedae ethanolic extract (EET)
has a protective action against gastric lesions in rats
(Twardowschy et al., 2008; Pereira et al., 2012) and a recent
study by Freitas et al. (2010) showed that the acute administra-
tion of EET exerts an antidepressant-like effect in the tail
suspension test (TST), a behavioral test used to assess the efﬁcacy
of antidepressant compounds (Steru et al., 1985). The
antidepressant-like action of EET was shown to be mediated by
an activation of the monoaminergic systems. Furthermore, EET
produced a synergistic antidepressant-like effect when combined
with conventional antidepressants in the TST (Freitas et al., 2010).
However, there is no study reporting the ability of Tabebuia
avellanedae to abolish depressive-like behavior induced by a
model of depression that mimics several symptoms observed in
depressed patients.
The olfactory bulbectomy (OB) is a well-established animal
model of depression capable of detecting antidepressant activity
almost exclusively following chronic treatment (Leonard and
Tuite, 1981). OB has been proposed as an animal model of
depression in terms of construct validity, since it induces altera-
tions in behavior, and in the endocrine, immune and neurotrans-
mitter systems that reproduces many of those seen in patients
with depression (Kelly et al., 1997; Leonard and Tuite, 1981).
Noteworthy, the OB model standardized by our group in female
mice reproduces depressive-like behaviors (Freitas et al., 2012;
Machado et al., 2012a,b) and activates hippocampal cell signaling
pathways implicated in synaptic plasticity, namely extracellular
signal-regulated kinase (ERK) 1, cyclic-AMP responsive-element
binding protein (CREB), and brain-derived-neurotrophic factor
(BDNF), without altering phosphatidylinositol 30-kinase (PI-3K)-
Akt and glycogen synthase kinase-3b (GSK-3b) phosphorylation
(Freitas et al., 2012).
Considering the information mentioned above, the aims of this
study were to examine the ability of the repeated (14 days) p.o.
administration of EET to alter hippocampal Akt, GSK-3b, ERK1/2
and CREB phosphorylation and BDNF immunocontent and to
reverse behavioral and biochemical changes induced by OB.2. Methods and materials
2.1. Plant material and preparation of EET
Tabebuia avellanedae barks were provided by Chamel Indu´stria
e Come´rcio de Produtos Naturais Ltda (Campo Largo, Brazil), lot
4753. The identiﬁcation was performed by the botanist Elide
Pereira dos Santos and a voucher specimen has been deposited at
the Herbarium of the Department of Botany at the Universidade
Federal do Parana´ (UFPR), Brazil. Dried and powdered barks (5 kg)were extracted three times by maceration with 95% ethanol for
7 days at room temperature. The combined ethanolic extract was
ﬁltered, the solvent evaporated under reduced pressure (40–
50 1C) and lyophilized to give a red-brown solid (919.2 g; 18.4%
yield), as described previously (Pereira et al., 2012).
2.2. Phytochemical analyses of EET
The analyses of EET was performed in a capillary electrophor-
esis system (CE) (HP3DCE, Agilent Technologies, Palo Alto, CA,
USA) equipped with a diode array detector set a 200 nm.
The measurements were conducted at 25 1C in an uncoated fused-
silica capillary (48.5 cm50 mm I.D.375 mm O.D.) obtained from
Polymicro (Phoenix, AZ, USA). In the ﬁrst conditioning, the capillary
was washed for 30min with sodium hydroxide 1.0 M followed by
deionized water for 30 min. Between runs the capillary was rinsed
for 5 min with running electrolyte (sodium tetraborate 20mmol L1
and methanol 10%, pH 9.0). Standard solutions and samples were
introduced from the inlet capillary extremity and injected hydro-
dynamically at 50 mbar (50 mbar¼4996.2 Pa) for 6 s. The applied
separation voltage was 30 kV, positive polarity in the injection side.
Caffeic acid (100mg/L) was utilized as internal standard and detec-
tion at 330 nm. Data acquisition and treatment were performed with
HP Chemstation software. Sample preparation: 0.5299 g of EET were
solubilized into 10mL of methanol:water 50% (v/v). As reported
previously (Pereira et al., 2012), the following compounds were
identiﬁed by the electropherogram of a sample of EET: p-hydro-
xybenzoic acid, anisic acid, veratric acid and caffeic acid.
2.3. Animals
Female Swiss mice (50–55 days, 35–40 g) were maintained at
constant room temperature (20–22 1C) with free access to water
and food, under a 12:12 h light:dark cycle (lights on at 07:00 h).
The cages were placed in the experimental room 24 h before the
test for acclimatization. All manipulations were carried out
between 9:00 and 17:00 h, with each animal used only once.
The procedures in this study were performed in accordance with
the NIH Guide for the Care and Use of Laboratory Animals and
approved by the local Ethics Committee. All efforts were made to
minimize animal suffering and the number of animals used in the
experiments.
2.4. Surgical procedure
After a 2-week acclimatization period, bilateral OB was per-
formed by suction method described previously by Leonard and
Tuite (1981) and standardized in our laboratory (Freitas et al.,
2012; Machado et al., 2012a,b). Animals were randomly divided
into two groups: one group underwent OB and the other under-
went sham operations. Brieﬂy, the mice were anesthetized with a
combination of xylazine (6 mg/kg, i.p.) and ketamine (100mg/kg, i.p.)
diluted in saline. An incision wasmade in the skin overlying the skull,
and, after exposure of the skull, holes were drilled on both sides of
the mid-line. Then the olfactory bulbs were bilaterally aspired by
blunt hypodermic needle (with for 1.0–1.2 cm long and with a
rounded tip of 0.80–1.2 mm of diameter) attached to a 10-ml syringe
that was used to create suction. Care was taken to avoid damaging
the frontal cortex. To stop the bleeding, the holes were ﬁlled with
swabs and covered with dental cement. All surgical procedure was
carried out employing alcohol 70% to eliminate contaminations.
Sham-operated animals underwent all of the same surgical proce-
dures, but the olfactory bulbs were left intact. The mice were allowed
to recover under a warming lamp to help with body temperature
maintenance. Each animal was given 14 days to recover from the
Fig. 1. Diagram of the experimental schedule. The effect of OB on locomotor activity was assessed in the open-ﬁeld paradigm in 3 time periods: pre-surgically, after
2 weeks of surgery, and 2 weeks post-treatment. Prior to the start of the treatment protocols, the animals were given 14 days to recover from their surgeries. EET doses of
10 and 30 mg/kg (p.o.) was administered once daily for 14 days. Twenty-four hours after the last administration, the mice were submitted to the open-ﬁeld, splash test 1 h
later, and after 1 h to the tail suspension test. Immediately after the conclusion of the behavioral tests, hippocampi were rapidly dissected and prepared to western
blot assay.
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2012).
2.5. Drugs and treatment
EET (10–100 mg/kg) was dissolved in distilled water with 5%
Tween 80 and was administered by oral route (p.o.) by gavage.
The dissolution of EET was freshly done from the lyophilized
power immediately before its administration. A control group
received distilled water with 5% Tween 80 as vehicle. All the
animals were fasted for 120 min before the oral treatment.
In the experiments designed to study the antidepressant-like
effect of the repeated treatment (for 14 days) of EET, the
immobility time in the TST and the locomotor activity in the
open-ﬁeld were assessed in independent groups of mice 24 h
after the last daily administration of EET (10–100 mg/kg, p.o.).
This experiment was carried out in order to choose the doses of
EET to be used in order to investigate its ability to abolish the
depressive-like behavior induced by OB.
As shown in Fig. 1, two weeks after surgery, EET (10–30 mg/kg,
p.o.) was administered once daily for 14 days. Animals were
assigned to the following groups: (a) sham/vehicle, (b) sham/
extract 10 mg/kg, (c) sham/extract 30 mg/kg, (d) OB/vehicle,
(e) OB/extract 10 mg/kg and (f) OB/extract 30 mg/kg. Number of
mice per group was 9–12.
2.6. Open-ﬁeld test
The OB model of depression reproduces in preclinical assays
the psychomotor agitation consistent with that is observed in
agitated depression (Zueger et al., 2005). To assess the effects of
OB on locomotor activity, mice were evaluated in the open-ﬁeld
paradigm as previously described (Freitas et al., 2012). The test
was consecutively performed in 3 time periods: pre-surgically,
2 weeks after surgery, and post-treatment (after 2 weeks of
ﬂuoxetine or water p.o. treatment). The number of squares
crossed with all paws (crossings) was counted in a 6 min session.
The apparatus was cleaned with a solution of 10% ethanol
between tests to remove any traces of each animal.
2.7. Tail suspension test (TST)
The total duration of immobility induced by tail suspension
was measured according to the method described by Steru et al.
(1985). Mice both acoustically and visually isolated were sus-
pended 50 cm above the ﬂoor by adhesive tape placed approxi-
mately 1 cm from the tip of the tail. Immobility time was
registered during a 6-min period (Machado et al., 2009; Freitas
et al., 2010).2.8. Splash test
The splash test was carried out 24 h after the last repeated
drug administration as described by Isingrini et al. (2010), with
minor modiﬁcations as performed previously (Freitas et al., 2012;
Machado et al., 2012a,b). The test consists of squirting a 10%
sucrose solution on the dorsal coat of a mouse placed individually
in clear Plexiglas boxes (9711 cm). Because of its viscosity,
the sucrose solution dirties the mouse fur and animals initiate
grooming behavior. After applying sucrose solution, the latency to
grooming and the grooming time were manually recorded for a
period of 5 minutes as an index of self-care and motivational
behavior. The apparatus were cleaned with a solution of 10%
ethanol between tests to remove any traces of each animal.
2.9. Western blot
After 2 weeks of treatment, and 24 h after the last adminis-
tration of extract or vehicle by oral rote, mice were decapitated.
Brains were removed and the lesion was estimated macroscopically
immediately after brain removal; all brains with incomplete surgery
or cortex damage were discarded from the experiment. The hippo-
campus was rapidly dissected and placed in cold saline solution.
Western blot analysis was performed as previously described (Leal
et al., 2002; Cordova et al., 2004; Freitas et al., 2012). Brieﬂy,
hippocampal tissue were mechanically homogenized in 400 ml of
Tris-base 50 mM pH 7.0, EDTA 1 mM, sodium ﬂuoride 100 mM,
PMSF 0.1 mM, sodium vanadate 2 mM, Triton X-100 1%, glycerol
10%, and then incubated for 30 min in ice. Lysates were centrifuged
(10,000 g for 10 min, at 4 1C) to eliminate cellular debris, and
supernatants diluted 1/1 (v/v) in Tris-base 100 mM pH 6.8, EDTA
4 mM, SDS 8%, glycerol 16%. Protein content was estimated by the
method previously described by Peterson (1977) and concentration
calculated by a standard curve with bovine serum albumin. To
compare signals obtained, the same amount of protein (70 mg per
lane) for each sample was electrophoresed in 10% SDS-PAGE
minigels (after addition of bromophenol blue 0.2% and b-mercap-
toethanol 8%) and transferred to nitro-cellulose or polyvinylidene
ﬂuoride membranes. To verify the efﬁciency of the transfer process,
the gels were stained with Coomassie blue (Coomassie blue R-250
0.1%, methanol 50%, acetic acid 7%) and membranes with Ponceau
0.5% in acetic acid 1%.
After this process, blots were incubated in a blocking solution (5%
non-fat dry milk in Tris buffer saline solution, TBS) for 1 h at room
temperature and then probed at 4 1C with anti-phospho-Akt (Sigma
Chemical Co., 1:1000), anti-phospho-CREB (Ser133) (Cell Signaling,
1:1000), anti-phospho-GSK-3b (Cell Signaling, 1:1000), anti-phos-
pho-ERK1/2 (Cell Signaling, 1:2000), anti-ERK1/2 (Sigma Chemi-
cal, 1:40000), anti-Akt (Sigma Chemical, 1:1000), anti-GSK-3b
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BDNF (Millipore, 1:1000), all in TBS containing 0.05% Tween 20
(TBS-T). Next, the membranes were incubated with anti-rabbit horse
radish peroxidase (HRP)-conjugated secondary antibody (1:5000)
for 1 h and the immunoreactive bands were developed by chemi-
luminescence (LumiGLOs, Cell Signaling, Beverly, MA, USA). All
blocking and incubation steps were followed by three washes
(5 min) of the membranes with TBS-T. In order to detect phos-
phorylated and total forms of ERK1/2, Akt and CREB in the same
membrane, the immunocomplexes were stripped as previously
described (Posser et al., 2007). Brieﬂy, membranes were washed
once with deionized water (5 min), followed by incubation with
NaOH 0.2 M (5 min), washing with deionized water (5 min) and
with TBST (10 min). The membranes that had been stripped of
immunocomplexes were subsequently blocked and treated accord-
ing to the same protocol as the one described above. In order to
ascertain the same protein load for each experimental group, the
expression level of a house keeping protein, b-actin, was evaluated
using a mouse anti-b-actin antibody (Santa Cruz, 1:1000) and anti-
mouse HRP-conjugated (Millipore 1:4000) secondary antibody.
The optical density (O.D.) of the bands was quantiﬁed using
Scion Image softwares. The phosphorylation levels of Akt, CREB,
GSK-3b and ERK1/2 were determined as ratios of O.D. of the
phosphorylated band to the O.D. of total bands. The immunocon-
tent of BDNF was determined making the relationship between
the O.D of BDNF band and the O.D of the b actin band.2.10. Statistical analysis
Comparisons between experimental and control groups were
performed by one-way (dose-response curve of EET in the TST) or
two-way ANOVA (experiments dealing with the ability of EET to
abolish OB induced alterations) followed by Duncan’s multiple
range test, when appropriate. Po0.05 was considered signiﬁcant.Fig. 3. Effect of the repeated (14 days) treatment of bulbectomized mice with EET
(10–30 mg/kg, p.o.) in the locomotor activity in the open-ﬁeld test. Each column
represents the meanþS.E.M. of 9–12 animals. Statistical analysis was performed
by two-way ANOVA, followed by the Duncan’s test. **Po0.01 as compared with
the control group (Sham-vehicle); ##Po0.01 as compared with the OB-vehicle
group.3. Results
3.1. Effect of the repeated administration of EET on the immobility
time in the TST and locomotor activity in the open-ﬁeld test
The results depicted in Fig. 2a shows that EET given by oral
route for 14 days decreased the immobility time in the TST, a
behavioral proﬁle characteristic of an antidepressant-like effect.
One-way ANOVA revealed a signiﬁcant effect of the extract
[F(3,29)¼4.42, Po0.01]. Post hoc analysis indicated a signiﬁcant
decrease in the immobility time elicited by EET at doses of 10 and
30 mg/kg. Fig. 2b shows that the administration of EET for 14 days
(dose range 10–100 mg/kg, p.o.) produced no effect in theFig. 2. Effect of repeated (14 days) administration of EET (dose range 10–100 mg/kg, p
meanþS.E.M. (n¼7–9). Statistical analysis was performed by one-way ANOVA, followlocomotor activity assessed in the open-ﬁeld test [F(3,30)¼0.10,
P¼0.96].
3.2. Effect of the repeated treatment with EET on hyperactivity
induced by OB
The results presented in Fig. 3 shows that the repeated
administration of EET (10 and 30 mg/kg, p.o.) abolished the
hyperactivity induced by OB in the open-ﬁeld test. A two-way
ANOVA revealed signiﬁcant differences for OB [F(1,52)¼68.87,
Po0.01], EET treatment [F(2,52)¼10.74, Po0.01] and OB EET
treatment interaction [F(2,52)¼4.49, P¼0o0.1]. Post hoc ana-
lyses indicated that EET (10 and 30 mg/kg, p.o.) treatment for 14
days prevented the hyperactivity caused by OB.
3.3. Effect of EET administration (14 days) on anhedonic-like
behavior induced by OB
The results depicted in Fig. 4a shows that the increase in
latency to grooming, an indicative of loss of self-care and
motivational behavior, produced by OB was signiﬁcantly blocked
by EET (10 and 30 mg/kg, p.o.) treatment. The two-way ANOVA
revealed signiﬁcant differences for OB [F(1,51)¼7.99, Po0.01],
EET treatment [F(2,51)¼4.04, Po0.05] and OBEET treatment
interaction [F(2,51)¼4.52, Po0.01]. Also, Fig. 4b shows that the
reduced grooming time caused by OB, another parameter that
indicates a loss of self-care and motivational behavior, was
signiﬁcantly abolished by the extract. A two-way ANOVA revealed
signiﬁcant differences for OB [F(1,54)¼24.02, Po0.01], EET treat-
ment [F(2,54)¼3.99, Po0.05] and OBEET treatment interaction
[F(2,54)¼15.93, Po0.01]..o.) in the TST (panel a) and open-ﬁeld test (panel b). Each column represents the
ed by Duncan’s test. *Po0.05 as compared with the vehicle-treated group (C).
Fig. 4. Effect of the repeated (14 days) treatment of bulbectomized mice with EET (10–30 mg/kg, p.o.) in the latency to grooming (panel a) and grooming time (panel b) in
the splash test. Each column represents the meanþS.E.M. (n¼9–10). Statistical analysis was performed by two-way ANOVA, followed by the Duncan’s test. **Po0.01 as
compared with the control group (Sham-vehicle); ##Po0.01 as compared with the OB-vehicle group.
Fig. 5. Effect of the repeated (14 days) treatment of bulbectomized mice with EET
(10–30 mg/kg, p.o.) in the immobility-time in the TST. Each column represents the
meanþS.E.M. of 9–12 animals. Statistical analysis was performed by two-way
ANOVA, followed by the Duncan’s test. **Po0.01 as compared with the control
group (Sham-vehicle); ##Po0.01 as compared with the OB-vehicle group.
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behavior induced by OB
Fig. 5 illustrates that the increase in the immobility time
produced by OB was signiﬁcantly abolished by EET (10 and
30 mg/kg, p.o.) treatment during 14 days. The two-way ANOVA
revealed a signiﬁcant main effect of EET treatment [F(2,43)¼
27.52, Po0.01], and OB EET treatment interaction [F(2,43)¼
4.06, Po0.05], but did not show a signiﬁcant main effect of OB
[F(1,43)¼0.44, P¼0.51].
3.5. Evaluation of Akt, GSK-3b, ERK1/2 and CREB phosphorylation
and BDNF immunocontent by Western blot assay
Akt is a serine/threonine kinase activated by phosphorylation
at Ser473 residue (Yang et al., 2002). Western blot analysis from
hippocampal tissue homogenates showed that neither the OB
procedure nor the repeated treatment with EET altered Akt
phosphorylation in hippocampus of mice (Fig. 6B). The two-way
ANOVA revealed no differences for OB [F(1,18)¼0.31, P¼0.58],
EET treatment [F(2,18)¼0.14, P¼0.86] and OBEET treatment
interaction [F(2,18)¼0.28, P¼0.76]. Fig. 6D shows that the treat-
ment of Sham or OB-mice with EET (30 mg/kg, p.o.) caused a
signiﬁcant increase in GSK-3b phosphorylation (Ser9) as com-
pared with Sham-operated group or OB-vehicle group, respec-
tively. The two-way ANOVA revealed a signiﬁcant main effect of
EET treatment [F(2,18)¼7.52, Po0.01], but did not show a
signiﬁcant effect of OB [F(1,18)¼3.35, P¼0.08] and OB EET
treatment interaction [F(2,18)¼0.002, P¼0.99].
The results depicted in Fig. 7B illustrates that the increase in ERK1
phosphorylation produced by OB was signiﬁcantly abolished by EET(10 and 30mg/kg, p.o.) treatment during 14 days. The two-way
ANOVA revealed a signiﬁcant main effect of OB [F(1,18)¼5.44,
Po0.05], and OBEET treatment interaction [F(2,18)¼4.56, Po
0.05], but did not show a signiﬁcant main effect of EET treatment
[F(2,18)¼0.94, P¼0.40]. Fig. 7C illustrates that ERK2 phosphorylation
was not altered in any experimental condition. The two-way ANOVA
revealed no differences for OB [F(1,18)¼2.25, P¼0.15], EET treat-
ment [F(2,18)¼0.81, P¼0.46], and OB EET treatment interaction
[F(2,18)¼1.23, P¼0.32].
Finally, the effect of the repeated treatment of OB-mice with
EET on CREB phosphorylation and BDNF immunocontent were
veriﬁed by western blot assay. Fig. 8B shows that EET (10 and
30 mg/kg, p.o.) administration and OB caused a signiﬁcant
increase in CREB phosphorylation (Ser133). The two-way ANOVA
revealed a signiﬁcant main effect for OB [F(1,14)¼6.78, Po0.05]
and EET treatment [F(2,14)¼3.50, Po0.05], but not for OB EET
treatment interaction [F(2,14)¼2.59, P¼0.11]. Fig. 8D shows that
the repeated treatment of OB-mice with EET at doses of 10 and
30 mg/kg (p.o.) was able to prevent the BDNF immunocontent
augmentation caused by olfactory bulbs ablation. The two-way
ANOVA revealed a signiﬁcant main effect for OB [F(1,18)¼7.68,
Po0.01] and OB EET treatment interaction [F(2,18)¼3.93,
Po0.05], but not for EET treatment [F(2,18)¼0.54, P¼0.59].4. Discussion
This study supports pharmacological and biochemical
evidence for the antidepressant-like effect of the EET adminis-
tered chronically by oral route to mice. The phytochemical
analyses of the EET identiﬁed the following compounds: p-
hydroxybenzoic acid, anisic acid, veratric acid and caffeic acid,
as reported previously (Pereira et al., 2012). Data from literature
have shown that p-hydroxybenzoic acid has antimicrobial proper-
ties (Sa´nchez-Maldonado et al., 2011), anisic acid is an anti-
inﬂammatory compound (Singh et al., 2006), veratric acid is
antihypertensive and antioxidant (Saravanakumar and Raja,
2011) and caffeic acid is an antioxidant compound (Simic´ et al.,
2007) that has antidepressant effects (Takeda et al., 2002, 2003,
2006; Dzitoyeva et al., 2008). Thus, it is likely that caffeic acid
alone or in combination with the other compounds identiﬁed in
EET contributes to the antidepressant action of Tabebuia
avellanedae.
In the present work, we demonstrated that EET administered for
14 days produced a signiﬁcant antidepressant-like effect in the TST, a
commonly used behavioral test that predict the efﬁcacy of anti-
depressant treatment (Steru et al., 1985; Bourin et al., 2005;).
Additionally, a consistent antidepressant-like activity of EET in a
well-established animal model of depression, the olfactory bulbect-
omymodel (Leonard and Tuite, 1981), was shown. Noteworthy, this
Fig. 6. Effect of repeated (14 days) treatment of bulbectomized mice with EET (10–30 mg/kg, p.o.) on Akt (panels A and B) and GSK-3b (panels C and D) phosphorylation.
Panels A and C show a representative western blot of the phosphorylation and total content of Akt and GSK-3b. Quantitative analyses are illustrated in panels B and D. The
data are expressed as ratio of optic density (O.D.) between phosporylated (P-Akt, P-GSK-3b) and total (T-Akt, T-GSK-3b) forms of Akt and GSK-3b. Each column represents
the meanþS.E.M. of 4 independent experiments. Statistical analysis was performed by two-way ANOVA, followed by the Duncan’s test. *Po0.05 as compared with the
control group (Sham-vehicle); # Po0.05 as compared with the OB-vehicle group. Abbreviations: sham/vehicle (S-Ct), sham/extract 10 mg/kg (S-E10), sham/extract 30 mg/
kg (S-E30), OB/vehicle (B-Ct), OB/extract 10 mg/kg (B-E10) and OB/extract 30 mg/kg (B-E30) groups.
Fig. 7. Effect of repeated (14 days) treatment of bulbectomized mice with EET
(dose range 10–30 mg/kg, p.o.) on ERK1 (panels A and B) and ERK2 (panels A and
C) phosphorylation. Panel A shows a representative western blot of phosphory-
lated and total forms of ERK1 and ERK2. Quantitative analyses are illustrated in
panels B and C. The data are expressed as ratio between phosphorylated (P-ERK1
and P-ERK2) and total (T-ERK1 and T-ERK2) forms. Each column represents the
meanþS.E.M. of 4 independent experiments. Statistical analysis was performed by
two-way ANOVA, followed by Duncan’s test. *Po0.05, **Po0.01 as compared
with the control group (Sham-vehicle); #Po0.05 as compared with the OB-
vehicle group. Abbreviations: sham/vehicle (S-Ct), sham/extract 10 mg/kg
(S-E10), sham/extract 30 mg/kg (S-E30), OB/vehicle (B-Ct), OB/extract 10 mg/kg
(B-E10) and OB/extract 30 mg/kg (B-E30) groups.
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behavioral changes reported in the literature, particularly the
hyperlocomotion in the open-ﬁeld test, the anhedonic-like behavior
in the splash test and the increased immobility time in the TST
(Freitas et al., 2012; Machado et al., 2012a,b). In the present study,
the treatment for 14 days with EET in bulbectomized mice was
effective in preventing these behavioral alterations induced by
olfactory bulbs ablation. OB caused a signiﬁcant increase in CREB
(Ser133) and ERK1 phosphorylation levels and BDNF immunocon-
tent. This result concurs with the ﬁndings of a previous study from
our group (Freitas et al., 2012). EET per se caused an augmenta-
tion of both CREB (Ser133) and GSK-3b (Ser9) phosphorylation. In
addition, it was able to abolish the enhancement in ERK1 phos-
phorylation and BDNF immunocontent induced by OB. Neither EET
nor OB caused alterations in Akt (Ser473) phosphorylation. Alto-
gether, the results indicate that the antidepressant-like action of
EET is accompanied by modulation of GSK-3b, ERK1, CREB and
BDNF-mediated signaling pathways which are well-known to be
implicated in the neuroplasticity alterations evoked by antidepres-
sants (Covington et al., 2010; Vialou et al., 2012).
The TST is a predictive animal test widely used for screening
antidepressant activity of different classes of drugs (Porsolt et al.,
1977; Cryan et al., 2005). This test is based on the observation
that animals, after initial escape-oriented movements, develop an
immobile posture when placed in an inescapable stressful situa-
tion. When antidepressant treatments are given prior to the tests,
the subjects will actively persist engaging in escape-directed
behavior for longer periods of time than after vehicle treatment
(Cryan et al., 2005). Recently, our group showed that an acute
administration of EET produced an antidepressant-like effect in
the TST in mice (Freitas et al., 2010). In the present study, the
treatment of mice for 14 days with EET at dose of 10 and 30 mg/kg
(p.o.) produced a signiﬁcant antidepressant-like effect in the TST
in agreement with the fact that antidepressant drugs produce
a reduction in the immobility time in this predictive test (Steru
et al., 1985). This experiment show that no tolerance was veriﬁed
following repeated treatment of EET at doses of 10 and 30 mg/kg
(p.o.), since the extract administered acutely causes an anti-
depressant-like effect in the TST at the doses of 10, 30, 100 and
300 mg/kg (p.o.) (Freitas et al., 2010).
Fig. 8. Effect of repeated (14 days) treatment of bulbectomized mice with EET (dose range 10–30 mg/kg, p.o.) on CREB (panels A and B) phosphorylation and BDNF (panels
C and D) immunocontent. Panels A and C show a representative western blot of total and phosphorylated forms of CREB. Quantitative analyses are illustrated in panels B
and D. The data are expressed as ratio between phosphorylated (P-CREB) and total (T-CREB) forms of CREB and as ratio between BDNF content and b-actin. Each column
represents the meanþS.E.M. of 4 independent experiments. Statistical analysis was performed by two-way ANOVA, followed by Duncan’s test. *Po0.05, **Po0.01 as
compared with the control group (Sham-vehicle); #Po0.05 as compared with the OB-vehicle group. Abbreviations: sham/vehicle (S-Ct), sham/extract 10 mg/kg (S-E10),
sham/extract 30 mg/kg (S-E30), OB/vehicle (B-Ct), OB/extract 10 mg/kg (B-E10) and OB/extract 30 mg/kg (B-E30) groups.
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EET was capable of reversing depressive-like behaviors induced
by OB. Olfactory bulbs ablation induces learning and memory
dysfunctions, psychomotor agitation, altered avoidance behavior
and anhedonic-like behavior (Kelly et al., 1997). These effects do
not appear to be due to anosmia, as selective ablation of the
olfactory sensory receptors does not produce these OB-induced
symptoms (Alberts and Friedman, 1972; Saitoh et al., 2006).
In the present work, the OB produced a signiﬁcant hyperlocomo-
tion consistent with clinical symptoms of agitated depression that
was prevented by the treatment (14 days) of OB-mice with EET at
doses of 10 and 30 mg/kg (p.o.). The ability of EET to block
symptoms of agitated depression reinforces the antidepressant-
like property of this plant and corroborates with several studies
that have shown that antidepressant compounds are able to
prevent the hyperactivity induced by OB such as curcumin, the
active constituent of Curcuma longa (Xu et al., 2005) and the
hydroalcoholic extract from Rosmarinus ofﬁcinalis L. (Machado
et al., 2012a).
In the present work, OB produced a signiﬁcant increase in the
immobility time in the TST, an indicative of a depressive-like
behavior. This result is in agreement with the ﬁndings of a
previous study by our group (Carlini et al., 2012) that shows that
olfactory bulbs ablation produces a depressive-related behavior in
the TST. Of note, this behavioral alteration was prevented by EET
at doses of 10 and 30 mg/kg (p.o.) once a day for 14 days,
reinforcing the notion that EET exerts an antidepressant-like
effect.
This study assessed anhedonic-like behavior that is related to
the inability to experience pleasure, through the splash test in
mice. In this test, an increase in the latency to start the grooming
behavior as well as a decrease in the total grooming time
indicates a loss of self-care and motivational behavior, suggestive
of an anhedonic-like behavior (Kalueff and Tuohimaa, 2004).
A study by Gambarana et al. (2001) shows that the hydroalcoholic
extract from Hypericum perforatum was effective in preventing
anhedonia in an animal model based on the ﬁnding that repeated
stressors prevent the development of appetitive behavior induced
by vanilla sugar in satiated rats fed ad libitum. In addition, Xu et al.
(2008) showed that a mixture of honokiol and magnolol, the main
constituents simultaneously identiﬁed in the barks of Magnolia
ofﬁcinalis, reversed chronic mild stress-induced reduction in sucroseconsumption in rats. Our results are in line with the notion that EET
(10 and 30 mg/kg, p.o.) act counteracting the loss in motivational
and self-care behavior induced by OB. This suggests that compo-
nents of EET are attractive candidates for further studies and, after
conﬁrming safety and effectiveness, clinical trial can address the
usefulness for the management of depression associated with
anhedonia.
A new class of putative antidepressant agents that act as GSK-
3b inhibitors has been proposed. The primary mechanism of
regulation of this enzyme involves enzyme inhibition through
phosphorylation of Ser9 (Peineau et al., 2008) by kinases such as
Akt/PKB,PKA, PKC, and ribosomal S6 kinase (Doble and Woodgett,
2003). Several studies have shown that treatment with antide-
pressants improve the phosphorylation of GSK-3b on Ser9 in
cerebral cortex (Li et al., 2004) and hippocampus (Eom and
Jope, 2009), causing enzyme inhibition. The novel GSK-3b inhi-
bitor thiadiazolidinone NP031115, and the well-established GSK-
3b inhibitor AR-A014418, were shown to produce antidepressant-
like effects in the mouse FST (Rosa et al., 2008). Furthermore, a
decrease in GSK-3b phosphorylation was also found in the
prefrontal cortex of suicide victims and has been associated with
major depressive disorders (Karege et al., 2006). Overall, these
results corroborate the idea that GSK-3b is an important target for
the action of antidepressant agents. Our results are consistent
with this notion, since EET-treated sham-operated or OB-mice
group (30 mg/kg, p.o.) presented a signiﬁcant increase in Ser9
GSK-3b phosphorylation in mouse hippocampus, as compared
with sham-vehicle or OB-vehicle group. The mechanism under-
ling the phosphorylation of GSK-3b in response to EET was not
identiﬁed in the present study, since this effect was not accom-
panied by activation of Akt, a well-known enzyme responsible for
Ser9 GSK-3b phosphorylation.
ERK1/2 are members of mitogen activated protein kinases
family activated by phosphorylation. ERK1/2 primarily regulates
neuronal growth, cell differentiation and apoptosis, as well as
synaptic plasticity (Stork and Schmitt, 2002; Thomas and
Huganir, 2004). Recent studies have shown that the hyperactivity
of Ras-ERK pathways may be implicated in the pathophysiology
of depression (Galeotti and Ghelardini, 2011; Elomaa et al., 2012).
Additionally, previous studies indicated that the antidepressant
treatments may inhibit ERK activity (Fumagalli et al., 2005; Bravo
et al., 2009). Our results support this notion, because the increase
A.E. Freitas et al. / Journal of Ethnopharmacology 145 (2013) 737–745744in ERK1 phosphorylation caused by OB was signiﬁcantly
prevented by EET (10 and 30 mg/kg, p.o.). On the other hand, in
the present study ERK2 phosphorylation was not altered in any
experimental group.
A number of growth factors and hormones have been shown to
stimulate the expression of genes involving Ser133 phosphorylation
of the nuclear factor CREB (Tardito et al., 2006). This phosphoryla-
tion promotes the association of CREB with the CREB-binding
protein, a co-activator protein that aids in the assembly of an
active transcription complex enabling the activation of target genes
(Lu et al., 2003). Data from the existing literature have shown that
antidepressant compounds such as natural ﬂavonols (Hou et al.,
2010) and hyperforin (Gibon et al., 2012), one of the main bioactive
compounds from Hypericum perforatum, up-regulates hippocampal
pCREB. In the present study, treatment for 14 days with EET
(10 and 30 mg/kg, p.o.) produced a signiﬁcant increase in CREB
phosphorylation in the hippocampus both in sham-operated and
bulbectomized mice.
It is well known that hippocampal brain-derived-neurotrophic
factor (BDNF) expression is dependent on CREB activation and
this event may be a mediator of the therapeutic responses to
antidepressants (Nair and Vaidya, 2006; Duman, 2009). Never-
theless, elevated hippocampal BDNF levels have been reported
in bulbectomized mice (Hellweg et al., 2007; Freitas et al., 2012).
In the present study, we identiﬁed a signiﬁcant OB-induced up-
regulation of BDNF content at hippocampal tissue that was
blocked by treatment (14 days) of bulbectomized mice with EET
at dose of 30 mg/kg (p.o.). It could be supposed that the increase
in BDNF content may result from a compensatory up-regulation
of this neurotrophin following OB that, interestingly, was pre-
vented by EET.5. Conclusion
The present study ﬁrstly indicates that the administration of
Tabebuia avellanedae during 14 days in mice is able to produce an
antidepressant-like effect in the TST that may be associated with
CREB (Ser133) and GSK-3b (Ser9) phosphorylation. Furthermore,
the repeated treatment with Tabebuia avellanedae was effective in
reversing the hyperactivity, anhedonic behavior and increased
immobility time in the TST induced by OB. This response is
accompanied by modulation of signaling pathways related with
neuronal survival, particularly ERK1 and BDNF. Finally, our results
indicate that this plant could constitute an attractive tool for the
treatment of depressive disorders, validating the traditional use of
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